RU2283841C2 - Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний - Google Patents

Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний Download PDF

Info

Publication number
RU2283841C2
RU2283841C2 RU2003134376/04A RU2003134376A RU2283841C2 RU 2283841 C2 RU2283841 C2 RU 2283841C2 RU 2003134376/04 A RU2003134376/04 A RU 2003134376/04A RU 2003134376 A RU2003134376 A RU 2003134376A RU 2283841 C2 RU2283841 C2 RU 2283841C2
Authority
RU
Russia
Prior art keywords
dimethoxy
oxy
urea
quinolyl
phenyl
Prior art date
Application number
RU2003134376/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003134376A (ru
Inventor
Казуо КУБО (JP)
Казуо КУБО
Теруюки САКАИ (JP)
Теруюки САКАИ
Рика НАГАО (JP)
Рика НАГАО
Ясунари ФУДЗИВАРА (JP)
Ясунари ФУДЗИВАРА
Тосиюки ИСОЕ (JP)
Тосиюки ИСОЕ
Казумаса ХАСЕГАВА (JP)
Казумаса ХАСЕГАВА
Original Assignee
Кирин Бир Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18980738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2283841(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кирин Бир Кабусики Кайся filed Critical Кирин Бир Кабусики Кайся
Publication of RU2003134376A publication Critical patent/RU2003134376A/ru
Application granted granted Critical
Publication of RU2283841C2 publication Critical patent/RU2283841C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polymerization Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
RU2003134376/04A 2001-04-27 2002-04-26 Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний RU2283841C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-132775 2001-04-27
JP2001132775 2001-04-27

Publications (2)

Publication Number Publication Date
RU2003134376A RU2003134376A (ru) 2005-04-20
RU2283841C2 true RU2283841C2 (ru) 2006-09-20

Family

ID=18980738

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003134376/04A RU2283841C2 (ru) 2001-04-27 2002-04-26 Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний

Country Status (24)

Country Link
US (2) US6821987B2 (Sortimente)
EP (2) EP1652847B1 (Sortimente)
JP (1) JP2010077131A (Sortimente)
KR (1) KR100879669B1 (Sortimente)
CN (1) CN1273466C (Sortimente)
AT (1) ATE396988T1 (Sortimente)
AU (1) AU2002255284B2 (Sortimente)
BE (1) BE2018C008I2 (Sortimente)
BR (1) BRPI0209216B8 (Sortimente)
CA (1) CA2445333C (Sortimente)
DE (2) DE60226912D1 (Sortimente)
DK (1) DK1382604T3 (Sortimente)
ES (1) ES2256466T3 (Sortimente)
FR (1) FR18C1006I2 (Sortimente)
IL (1) IL158459A0 (Sortimente)
MX (1) MXPA03009662A (Sortimente)
NL (1) NL300927I9 (Sortimente)
NO (2) NO326325B1 (Sortimente)
NZ (1) NZ529046A (Sortimente)
PL (1) PL209822B1 (Sortimente)
RU (1) RU2283841C2 (Sortimente)
TW (1) TWI324154B (Sortimente)
WO (1) WO2002088110A1 (Sortimente)
ZA (1) ZA200307861B (Sortimente)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2573633C2 (ru) * 2011-09-19 2016-01-27 Бейджин Конрунс Фармасьютикал Ко., Лтд. Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, а также применение при лечении заболеваний, вызванных аномальной активностью протеинкиназы и/или гистондеацетилазы

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153920B1 (en) * 1999-01-22 2003-10-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives
TWI281915B (en) * 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
MX242553B (es) * 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
RU2283841C2 (ru) 2001-04-27 2006-09-20 Кирин Бир Кабусики Кайся Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний
EP2088141A3 (en) * 2001-06-22 2009-11-18 Kirin Pharma Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
WO2003033472A1 (en) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
JPWO2003093238A1 (ja) * 2002-05-01 2005-09-08 麒麟麦酒株式会社 マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
JP3763414B2 (ja) 2002-10-21 2006-04-05 麒麟麦酒株式会社 Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
ES2436888T3 (es) * 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
AU2005207946A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
CA2579810C (en) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
WO2006108059A1 (en) * 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007026864A1 (ja) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. 崩壊性の改善された医薬組成物の製造方法
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
AU2007252506C1 (en) 2006-05-18 2012-07-19 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
JP5368096B2 (ja) * 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
KR101556269B1 (ko) 2007-08-29 2015-09-30 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제제
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
KR101601997B1 (ko) 2008-03-17 2016-03-17 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
EP2594566A4 (en) * 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
AU2011322597B2 (en) 2010-10-27 2015-09-10 Novartis Ag Dosing regimes for the treatment of ocular vascular disease
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102532116B (zh) * 2011-08-09 2015-01-21 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN102408418A (zh) * 2011-10-21 2012-04-11 武汉迈德森医药科技有限公司 Tivozanib酸性盐及其制备方法和晶型
EP2626073A1 (en) 2012-02-13 2013-08-14 Harmonic Pharma Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
KR20230152151A (ko) 2013-07-12 2023-11-02 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
EP4599890A3 (en) 2015-01-13 2025-10-29 Kyoto University Sunitinib for preventing and/or treating amyotrophic lateral sclerosis
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
EP3338779B1 (en) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
WO2018028591A1 (zh) * 2016-08-09 2018-02-15 殷建明 一种喹啉衍生物及其用途
CN106478621B (zh) * 2016-09-30 2018-12-25 遵义医学院 喹啉或喹唑啉类衍生物、制备方法及其应用
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
CN108341813B (zh) * 2017-01-24 2020-11-17 四川大学 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN108530455B (zh) * 2017-03-01 2021-01-12 北京赛特明强医药科技有限公司 脲取代的芳环连二噁烷并喹唑啉类化合物或药用盐或水合物及作为酪氨酸激酶抑制剂的应用
RU2769694C2 (ru) 2017-04-27 2022-04-05 Астразенека Аб C5-Анилинохиназолиновые соединения и их использование в лечении рака
WO2018197643A1 (en) * 2017-04-27 2018-11-01 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109553612B (zh) * 2017-09-26 2021-09-03 广西梧州制药（集团）股份有限公司 一种吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
CA3090829C (en) 2018-02-11 2023-05-09 Beijing Scitech-Mq Pharmaceuticals Limited Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
EP3876934A4 (en) 2018-11-05 2022-08-03 Aveo Pharmaceuticals, Inc. Use of tivozanib to treat subjects with refractory cancer
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
JP2024540411A (ja) 2021-11-08 2024-10-31 プロジェントス・セラピューティクス・インコーポレイテッド 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用
WO2023096651A1 (en) 2021-11-26 2023-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating bile duct cancers with tivozanib
EP4531927A1 (en) 2022-05-24 2025-04-09 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024095127A1 (en) 2022-10-31 2024-05-10 Pliva Hrvatska D.O.O. Solid state forms of tivozanib and process for preparation thereof
WO2024110606A1 (en) * 2022-11-25 2024-05-30 Synthon B.V. A process for preparation of cabozantinib or tivozanib
WO2025120654A1 (en) * 2023-12-05 2025-06-12 Natco Pharma Limited An improved process for the preparation of tivozanib hydrochloride hydrate
WO2025253311A1 (en) 2024-06-04 2025-12-11 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078079C1 (ru) * 1990-01-11 1997-04-27 Фармасиа и Дпджон С.п.А. Производные пирролзамещенных уреидов, и их фармацевтически приемлемые соли, способ их получения и фармацевтическая композиция, обладающая ингибирующей ангиогенезис активностью
EP0860433A1 (en) * 1995-11-07 1998-08-26 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2000043366A1 (en) * 1999-01-22 2000-07-27 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2728878B2 (ja) 1987-12-15 1998-03-18 大倉工業株式会社 中空押出成形板
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
DE1041982T1 (de) * 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
AU2198999A (en) * 1997-12-22 1999-07-12 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
TWI281915B (en) * 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
JP2002030083A (ja) 2000-07-18 2002-01-29 Kirin Brewery Co Ltd Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩
MX242553B (es) * 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
RU2283841C2 (ru) 2001-04-27 2006-09-20 Кирин Бир Кабусики Кайся Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078079C1 (ru) * 1990-01-11 1997-04-27 Фармасиа и Дпджон С.п.А. Производные пирролзамещенных уреидов, и их фармацевтически приемлемые соли, способ их получения и фармацевтическая композиция, обладающая ингибирующей ангиогенезис активностью
EP0860433A1 (en) * 1995-11-07 1998-08-26 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2000043366A1 (en) * 1999-01-22 2000-07-27 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2573633C2 (ru) * 2011-09-19 2016-01-27 Бейджин Конрунс Фармасьютикал Ко., Лтд. Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, а также применение при лечении заболеваний, вызванных аномальной активностью протеинкиназы и/или гистондеацетилазы

Also Published As

Publication number Publication date
NL300927I9 (nl) 2019-02-05
US20030087907A1 (en) 2003-05-08
ZA200307861B (en) 2004-10-08
DE60226912D1 (de) 2008-07-10
NO20034595L (no) 2003-12-19
AU2002255284B2 (en) 2007-10-04
EP1652847B1 (en) 2008-05-28
RU2003134376A (ru) 2005-04-20
KR20040015143A (ko) 2004-02-18
JP2010077131A (ja) 2010-04-08
US7211587B2 (en) 2007-05-01
BE2018C008I2 (Sortimente) 2021-02-04
MXPA03009662A (es) 2004-12-06
NO2018005I1 (no) 2018-02-05
EP1382604A4 (en) 2004-09-08
TWI324154B (Sortimente) 2010-05-01
NZ529046A (en) 2005-10-28
NO20034595D0 (no) 2003-10-14
PL367105A1 (en) 2005-02-21
BRPI0209216B1 (pt) 2017-05-30
US20040229876A1 (en) 2004-11-18
EP1382604A1 (en) 2004-01-21
BRPI0209216B8 (pt) 2021-05-25
NO326325B1 (no) 2008-11-10
IL158459A0 (en) 2004-05-12
PL209822B1 (pl) 2011-10-31
EP1382604B1 (en) 2005-12-28
DK1382604T3 (da) 2006-04-18
FR18C1006I1 (fr) 2018-03-16
HK1070649A1 (en) 2005-06-24
CN1543459A (zh) 2004-11-03
DE60208364T2 (de) 2006-09-28
CA2445333A1 (en) 2002-11-07
ES2256466T3 (es) 2006-07-16
BR0209216A (pt) 2004-07-06
CN1273466C (zh) 2006-09-06
ATE396988T1 (de) 2008-06-15
WO2002088110A1 (en) 2002-11-07
FR18C1006I2 (fr) 2019-03-01
EP1652847A1 (en) 2006-05-03
EP1652847A3 (en) 2006-08-02
CA2445333C (en) 2011-03-22
US6821987B2 (en) 2004-11-23
NL300927I1 (nl) 2018-12-04
DE60208364D1 (de) 2006-02-02
KR100879669B1 (ko) 2009-01-21

Similar Documents

Publication Publication Date Title
RU2283841C2 (ru) Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний
JP3602513B2 (ja) アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
JP5982281B2 (ja) 医薬として有用な化合物
US9403812B2 (en) Triazole derivatives as Wnt signaling pathway inhibitors
JP5261575B2 (ja) 化学化合物
SK36599A3 (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin
KR20080040046A (ko) 티아졸 유도체
KR20010012926A (ko) 신규한 사이클릭 디아민 화합물 및 그것을 포함하는 의약
CN102558149A (zh) 嘧啶衍生物、及其制法和药物组合物与用途
CN101289444B (zh) 一种嘧啶衍生物及其医药用途
JP2008539186A (ja) 尿素誘導体、その製造方法、およびその使用
CN102558167A (zh) Gk和ppar双重激动活性的噻唑烷二酮衍生物
WO2018118868A1 (en) Triazole derivatives as tankyrase inhibitors
CN101463031A (zh) 吲唑及四氢吲唑类化合物及其制法和其药物组合物与用途
JPWO1998042680A1 (ja) 新規なアニリド化合物及びこれを含有する医薬
JP2004224800A (ja) アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
JP2002322163A (ja) ピペラジン誘導体
CN113214222B (zh) N-(芳基磺酰基)-吲哚-2-甲酰胺类FBPase抑制剂及其用途
KR20230051939A (ko) 신규한 캡시드 조립 저해제
WO2023279280A1 (zh) N-(芳基磺酰基)-吲哚-2-甲酰胺类FBPase抑制剂及其用途
CN111362972A (zh) 一种苯并咪唑并[2,1-b]噻唑类化合物及其应用
CA2353897A1 (en) 1,4-benzodiazepinone derivatives and their use as integrin antagonists
JPH0940669A (ja) ベンズイミダゾール化合物

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC4A Invention patent assignment

Effective date: 20081031

HK4A Changes in a published invention
QB4A Licence on use of patent

Free format text: LICENCE

Effective date: 20160530

QB4A Licence on use of patent

Free format text: SUB-LICENCE

Effective date: 20161017

QC41 Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right

Free format text: SUB-LICENCE FORMERLY AGREED ON 20161017

Effective date: 20170210